All Clostridium butyricum MIYAIRI 588 articles
-
NewsChanging the gut microbiome boosts health outcomes for people newly diagnosed with metastatic kidney cancer
Researchers have developed a novel use of biotherapeutic product CBM588 in the treatment of cancer; new research suggests the agent adjusts people’s microbiome, possibly leading to enhanced effectiveness of FDA-approved cancer immunotherapies.
-
NewsStudy reveals worrying links between bacteremia and probiotic use
Researchers using whole-genome sequencing found that all identified Clostridium butyricum bacteremia strains were probiotic derivatives.
